ReviewJournal of enzyme inhibition and medicinal chemistry2023
Selected strategies to fight pathogenic bacteria.
Review in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Bacterial zinc metalloproteases as facilitators of pathogenic success: a review.Archives of microbiology · 2026Review
- Antibiotic Resistance Crisis: From Bacterial Bioprospecting to Artificial Intelligence.Environmental microbiology reports · 2025Review
- Recent Advances in Surface-Enhanced Raman Scattering for Pathogenic Bacteria Detection: A Review.Sensors (Basel, Switzerland) · 2025Review
- A comprehensive investigation of the anion inhibition profile of a β-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Sulfonamide-Based Inhibition of the β-Carbonic Anhydrase fromInternational journal of molecular sciences · 2024Article
- Bacterial synthesis of metal nanoparticles as antimicrobials.Microbial biotechnology · 2024Review
- Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-ResistantJournal of medicinal chemistry · 2024Article
- The good, the bad, and the ugly of metals as antimicrobials.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Review
- Exploring solute binding proteins in Pseudomonas aeruginosa that bind to γ-aminobutyrate and 5-aminovalerate and their role in activating sensor kinases.MicrobiologyOpen · 2024Article
- Antibacterial Properties of Rose Bengal Conjugated to Hyaluronic Acid.International journal of molecular sciences · 2024Article
- Comparative evaluation of small molecules reported to be inhibitors ofMicrobiology spectrum · 2024Article
- Integrating a Multi-label Deep Learning Approach with Protein Information to Compare Bioactive Peptides in Brain and Plasma.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamates.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Microalga Broths Synthesize Antibacterial and Non-Cytotoxic Silver Nanoparticles Showing Synergy with Antibiotics and Bacterial ROS Induction and Can Be Reused for Successive AgNP Batches.International journal of molecular sciences · 2023Article
- The Development of Alginate/Ag NPs/Caffeic Acid Composite Membranes as Adsorbents for Water Purification.Membranes · 2023Article
- Resistance, Tolerance, Virulence and Bacterial Pathogen Fitness-Current State and Envisioned Solutions for the Near Future.Pathogens (Basel, Switzerland) · 2023Review
- Optimal Concentration and Duration of Endotracheal Tube Coating to Achieve Optimal Antimicrobial Efficacy and Safety Balance: An In Vitro Study.Gels (Basel, Switzerland) · 2023Article
- Change in Long Non-Coding RNA Expression Profile Related to the Antagonistic Effect ofCurrent issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids are attractive antisense and antigene agents representing a novel strategy to target pathogens due to their unique mechanism of action. Antisense inhibition and development of antisense peptide nucleic acids is a new approach to antibacterial agents. Due to the increased resistance of biofilms to antibiotics, alternative therapeutic options are necessary. To develop antimicrobial strategies, optimised
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.